You are here

hemophilia A

Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study

Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study

Endpoints

Flag link:

Roche drug dramatically reduces bleeds in key hemophilia tests

Roche drug dramatically reduces bleeds in key hemophilia tests

Reuters

clinical trials

Flag link:

ASH17: Spark gene therapy falls behind BioMarin in hemophilia

ASH17: Spark gene therapy falls behind BioMarin in hemophilia

BioPharma Dive

Spark Therapeutics

Flag link:

ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia

ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia

BioPharma Dive

Flag link:

FDA Approves Genentech Hemophilia Drug, But Adds Safety Warning

FDA Approves Genentech Hemophilia Drug, But Adds Safety Warning

Xconomy

Flag link:

With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy

With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy

Endpoints

Flag link:

Bayer files longer-acting bleeding candidate to FDA

Bayer files longer-acting bleeding candidate to FDA

Fierce Biotech

Flag link:

Bioverativ taps patient social network for input on hemophilia trial design

Bioverativ taps patient social network for input on hemophilia trial design

Fierce Pharma

clinical trials

Flag link:

Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab

Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab

Endpoints

Flag link:

Spark offers a glimpse of efficacy in first two hemophilia A gene therapy patients

Spark offers a glimpse of efficacy in first two hemophilia A gene therapy patients

Endpoints

Spark Therapeutics

Flag link:

Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger

Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger

Endpoints

clinical trials

Flag link:

Shire writes off a shot at long-acting hemophilia drug after small study flops

Shire writes off a shot at long-acting hemophilia drug after small study flops

Endpoints

Xenetic Biosciences

clinical trials

Flag link:

Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal

Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal

Endpoints

Sangamo BioSciences

Flag link:

Roche claims that its interim update on hemophilia A drug is positive. But it’s hard to gauge.

Roche claims that its interim update on hemophilia A drug is positive. But it’s hard to gauge.

Endpoints

Flag link:

Roche gears up to enter loaded hemophilia A drug market

Roche gears up to enter loaded hemophilia A drug market

Medical Marketing and Media

Flag link:

Roche Finds Safe Haven In Emicizumab

Roche Finds Safe Haven In Emicizumab

Seeking Alpha

Flag link:

Roche readies a hunt for marketing OK on hemophilia blockbuster hopeful emicizumab after PhIII success

Roche readies a hunt for marketing OK on hemophilia blockbuster hopeful emicizumab after PhIII success

Endpoints

Flag link:

Hey, wait a second. What about Roche’s PhIII hemophilia A drug?

Hey, wait a second. What about Roche’s PhIII hemophilia A drug?

Endpoints

Flag link:

Germany's Bayer wins U.S. FDA approval for hemophilia A therapy

Germany's Bayer wins U.S. FDA approval for hemophilia A therapy

Yahoo/Reuters

Flag link:

5 Reasons Roche Thinks It Can Outclass the Competition

5 Reasons Roche Thinks It Can Outclass the Competition

Motley Fool

dry macular degeneration

Flag link:

Pages